Ann: Ethics Approval for BTX 1308 Psoriasis Patient Study Secured, page-89

Any company with out revenue is being hit across the board , Plus BOT had stripped away its comfort insulation of a higher SP..... still plenty of Potential Value here ,, as stated I have a chunk parked here,, but realistically December January for BOT to be making gains again on results ,,plus the market will want to see a deal on the table from these guys...with a dollar amount attached to it..... we know they are great at research and Science,, but the market want to see Business acumen and the ability to complete business negotiations with a positive commercial outcome for Shareholders...

Patience will be the key here....but at present the markets are not demonstrating a willingness to be patient,,, portfolios after yesterday are bleeding and Investors want their funds out of specs and into earners...

Usually I don't cross pollinate a thread but an example would be PAA, they have an Exit Option with Elanco when the Phase II Primary endpoint is met and they have the Epichem division bringing in 3m to 4m per year and Immuron with Travellan ,, even though the companies have ongoing research they have a couple of Million in revenue but they have satisfied the market they can complete a commercial deal...